A939572 _SCD1 抑制劑 - MedChemExpress_第1頁
A939572 _SCD1 抑制劑 - MedChemExpress_第2頁
A939572 _SCD1 抑制劑 - MedChemExpress_第3頁
A939572 _SCD1 抑制劑 - MedChemExpress_第4頁
全文預覽已結束

VIP免費下載

版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEA939572Cat. No.: HY-50709CAS No.: 1032229-33-6分式: CHClNO分量: 387.86作靶點: Stearoyl-CoA Desaturase (SCD)作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 56 mg/mL (1

2、44.38 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.5782 mL 12.8912 mL 25.7825 mL5 mM 0.5156 mL 2.5782 mL 5.1565 mL10 mM 0.2578 mL 1.2891 mL 2.5782 mL請根據產品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 A939572種服有效的硬脂酰 CoA 去飽和酶 1 SCD1 抑

3、制劑,作于 mSCD1 和 hSCD1,IC50 分別為 4nM 和 37 nM。IC50 & Target IC50: 1體外研究A939572 exhibits robust in vivo activity with dose-dependent desaturation index lowering effects 1.A9395721/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEis a small molecule that specifically inhibits SCD1 enzymatic activity. A939572

4、 demonstrates a significantdose-dependent decrease in proliferation in Caki1, A498, Caki2, and ACHN at day 5 (IC50s of 65 nM, 50 nM,65 nM, and 6 nM, respectively). In A939572 (SCDi) treated Caki1 and A498 cells, all five ER stress relatedgenes are expressed at significantly increased levels compared

5、 to DMSO+BSA control, and this elevatedexpression can be blocked with the addition of OA-BSA 2.體內研究 Athymic nude (nu/nu) mice bearing A498 ccRCC xenografts are treated with A939572 (30mg/kg, p.o.) andTem individually or in combination over the course of four weeks, and tumor volume (mm3) is recorded

6、.A939572 and Tem monotherapy generate similar growth responses with approximately 20-30% reductions intumor volume (vs. placebo control) being observed upon study completion, with values reaching statisticalsignificance only within the last week of treatment. The combination group yields over a 60%

7、decrease intumor volume (vs. placebo control) by study completion with significant reductions recorded afterapproximately 1 week of treatment 2.PROTOCOLCell Assay 2 Cells are plated (0.5 or 1105/well) in 24-well plates in triplicate. Cells are counted using a Coulter ParticleCounter. Oleic acid-albu

8、min is added to media at 5Mol. A939572 stocks are prepared in DMSO.Temsirolimus dosing is performed. Soft agar cultures are prepared by diluting 2 growth medium 1:1 in 1.5%SeaplaqueGTG agarose, with 500 cells/plate in 60mm culture dishes. Colonies are stained with Giemsaand counted after 3wks 2.MCE

9、has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 2 A498 cells are subcutaneously implanted in athymic nu/nu mice at 1106 cells/mouse in 50% Matrigel.Tumors reach 50 mm3 prior to 4 wk treatment. A939572 is re-suspended in strawberr

10、y flavored Kool-Aidin sterilized H2O (0.2 g/mL) vehicle at 30 mg/kg in a 50 L dose. Mice are orally fed by using a syringe toadminister the 50 L dose twice daily/mouse. This modified method is found to be effective and less stressfulon the mice. Temsirolimus is solubilized in 30% ethanol/saline and

11、administered via intraperitoneal injectionat 10 mg/kg in a 50 L dose once every 72 hrs/mouse. Tumor volumes are calculated using the formula0.5236 (L*W*H) and body weight are measured every 3 days.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發表的

12、科研獻 Oncogene. 2016 Jan 28;35(4):427-37. PLoS Pathog. 2018 Aug 17;14(8):e1007261. Stem Cells. 2018 Oct;36(10):1603-1616. J Cell Mol Med. 2019 Mar;23(3):2064-2076. Front Pharmacol. 2018 Jan 4;8:960.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChe

13、mEREFERENCES1. Xin Z, et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett. 2008 Aug1;18(15):4298-302.2. von Roemeling CA, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. ClinCancer Res. 2013 May 1;19(9):2368-80.McePdf

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
  • 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
  • 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論